Scientists are using a vaccine for a common virus called Epstein Barr (EBV) to stimulate human immune system to attack cancer cells.

Researchers recorded a heightened immune response to cancer cells infected with Epstein Barr Virus and initial tests has produced promising effects, according to a study by the University of Birmingham and the Royal Marsden Hospital, presented at the National Cancer Research Institute conference.

The new vaccine targets two proteins (EBNA1 and LMP2) that express in cancer cells infected with the virus.

EBV is a herpes virus that is widespread in all human populations. The virus usually causes no health problems, but is associated with a number of cancers, including lymphomas and nasopharyngeal carcinoma.

Scientists are increasingly looking for ways to use cancer vaccines to stimulate the body's immune system against tumors.